Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study

• Published in: Critical care medicine Vol. 47; no. 6; p. e470
• Main Authors: Li Bassi, Gianluigi, Motos, Ana, Fernandez-Barat, Laia, Aguilera Xiol, Eli, Chiurazzi, Chiara, Senussi, Tarek, Saco, Maria A, Fuster, Carla, Carbonara, Marco, Bobi, Joaquim, Amaro, Rosanel, De Rosa, Francesca, Comaru, Talitha, Yang, Hua, Ranzani, Otavio T, Marti, Joan-Daniel, Rinaudo, Mariano, Comino Trinidad, Oscar, Rigol, Montserrat, Bringué, Josep, Ramirez, Jose, Nicolau, David P, Pelosi, Paolo, Antonelli, Massimo, Blasi, Francesco, Artigas, Antonio, Montgomery, A Bruce, Torres, Antoni
• Format: Journal Article
• Language: English
• Published: United States 01.06.2019
• Subjects: Administration, Inhalation; Administration, Intravenous; Amikacin - administration & dosage; Amikacin - pharmacology; Animals; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - pharmacology; Bacterial Load - drug effects; Bronchoalveolar Lavage Fluid - microbiology; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fosfomycin - administration & dosage; Fosfomycin - pharmacology; Lung - microbiology; Lung - pathology; Meropenem - administration & dosage; Meropenem - pharmacology; Nebulizers and Vaporizers; Pneumonia - drug therapy; Pneumonia - microbiology; Pneumonia - pathology; Prospective Studies; Pseudomonas aeruginosa - drug effects; Pseudomonas Infections - complications; Pseudomonas Infections - drug therapy; Random Allocation; Swine; Trachea - metabolism; Trachea - microbiology

Latest trials failed to confirm merits of nebulized amikacin for critically ill patients with nosocomial pneumonia. We studied various nebulized and IV antibiotic regimens in a porcine model of severe Pseudomonas aeruginosa pneumonia, resistant to amikacin, fosfomycin, and susceptible to meropenem....